Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Immuron stock price, quote, forecast and news

IMC.AX
AU000000IMC7
A0RDPK

Price

0.10
Today +/-
+0
Today %
+0 %
P

Immuron stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Immuron stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Immuron stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Immuron stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Immuron's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Immuron Stock Price History

DateImmuron Price
9/16/20240.10 undefined
9/13/20240.10 undefined
9/12/20240.10 undefined
9/11/20240.10 undefined
9/10/20240.10 undefined
9/9/20240.10 undefined
9/6/20240.10 undefined
9/5/20240.10 undefined
9/4/20240.10 undefined
9/3/20240.10 undefined
9/2/20240.10 undefined
8/30/20240.10 undefined
8/28/20240.10 undefined
8/27/20240.11 undefined
8/26/20240.11 undefined
8/23/20240.11 undefined
8/22/20240.11 undefined
8/21/20240.11 undefined
8/20/20240.10 undefined
8/19/20240.10 undefined

Immuron Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Immuron, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Immuron from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Immuron’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Immuron. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Immuron’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Immuron’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Immuron’s growth potential.

Immuron Revenue, EBIT and net profit per share

DateImmuron RevenueImmuron EBITImmuron Net Income
20231.8 M undefined-3.44 M undefined-3.79 M undefined
2022765,190 undefined-3.12 M undefined-2.85 M undefined
2021145,780 undefined-7.2 M undefined-8.38 M undefined
20202.52 M undefined-3.07 M undefined-2.93 M undefined
20192.39 M undefined-4.69 M undefined-4.66 M undefined
20183.69 M undefined-2.83 M undefined-3.01 M undefined
20172.98 M undefined-6.64 M undefined-6.8 M undefined
20164 M undefined-5.25 M undefined-5.6 M undefined
20151.12 M undefined-3.41 M undefined-3.45 M undefined
20141.04 M undefined-1.95 M undefined-2.54 M undefined
2013150,000 undefined-2.97 M undefined-3.54 M undefined
2012460,000 undefined-2.54 M undefined-2.3 M undefined
2011300,000 undefined-2.81 M undefined-2.6 M undefined
2010500,000 undefined-2.17 M undefined-1.9 M undefined
2009550,000 undefined-2.54 M undefined-2.32 M undefined
20081.09 M undefined-3.21 M undefined-2.86 M undefined
20075.2 M undefined-3.56 M undefined-3.28 M undefined
20064.81 M undefined-3.27 M undefined-3.56 M undefined
20055.79 M undefined-1.63 M undefined-1.33 M undefined
20044.29 M undefined-1.49 M undefined-1.16 M undefined

Immuron Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
002345451000001132322001
---50.0033.3325.00-20.0025.00-80.00-------200.00-33.3350.00-33.33----
---33.3325.0040.0050.0020.00--------100.00100.00100.0050.0050.00--100.00
000112210000000032311001
0-1-1-1-1-1-3-3-3-2-2-2-2-2-1-3-5-6-2-4-3-7-3-3
---50.00-33.33-25.00-20.00-75.00-60.00-300.00------100.00-300.00-166.67-300.00-66.67-200.00-150.00---300.00
0-1-1-1-1-1-3-3-2-2-1-2-2-3-2-3-5-6-3-4-2-8-2-3
------200.00--33.33--50.00100.00-50.00-33.3350.0066.6720.00-50.0033.33-50.00300.00-75.0050.00
2.693.063.213.283.283.73.753.974.265.5110.6212.7513.9214.3342.2275.5876.44105.87133.66144.74176.39221.06227.58227.8
------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Immuron Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Immuron is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (k)INVENTORIES (M)OTHER CURRENT LIAB. (k)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (k)LONG-T. REC. (k)INTANGIBLE ASSETS (M)GOODWILL (k)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (k)OTHER SHORT-TERM LIAB. (k)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (k)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (k)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                               
4.364.843.382.511.313.662.530.671.090.151.880.751.441.456.143.122.293.994.735.123.2525.0522.1118.99
00.370.460.630.60.910.81.010.270.030.150.030.20.020.520.224.391.771.680.30.020.030.210.02
30206020106020004050503208000000670308.23306.16454.55398.39
0.090.320.430.60.81.291.590.820.160.10.020.290.210.290.571.152.062.340.50.540.80.290.330.84
2020405013013060150160120200504003904074.94168.37141.849.2933.1978.26572.4158.15
4.55.574.373.812.856.0552.651.680.442.31.172.211.847.624.538.818.277.056.684.4125.7523.6720.41
0.011.921.881.831.771.741.630.640.220.070.030.030.020.010.020.020.020.020.020.020.070.030.230.2
00000000000000000000000159.07
000000000000000000000306455398
00000000001.461.461.40.680000000000
0350330310290280000000000000000000
0000000000000000002.171.861.721.270.961.22
0.012.272.212.142.062.021.630.640.220.071.491.491.420.690.020.020.020.022.191.881.791.611.641.98
4.517.846.585.954.918.076.633.291.90.513.792.663.632.537.644.558.838.299.248.566.227.3625.3122.39
                                               
7.4612.0512.5912.5912.7416.9918.7318.7520.5821.4626.9627.7230.0231.3640.3340.3445.6353.6358.3760.5162.4388.3688.4488.44
000000000000000000000000
-3.02-4.57-6.27-7.55-8.71-10.04-13.55-16.83-19.5-21.64-23.6-25.99-27.97-31.21-33.54-36.99-40.69-47.06-49.93-53.16-56.9-62.57-65.37-68.93
00000000000000000000121.47106.51113.22112.21
000000000000000000000000
4.447.486.325.044.036.955.181.921.08-0.183.361.732.050.156.793.354.946.578.447.355.6425.923.1819.62
00.210.170.430.520.670.90.680.210.190.280.330.430.780.851.211.991.290.690.720.160.110.720.79
000000000000033000036.17114.01459.44300.57755.82623.69683.43
601508043029042049063058048016060052012000019.14020.9816.02238.65124.04706.02
0000000000000.080001.90.37000000
000103000000000000000042.1820.534.3838.77
0.060.360.250.870.841.091.391.310.790.670.440.931.031.230.851.213.891.710.81.20.521.121.52.22
0000.03000000000.561.150000000.02000
000000000000000000000000
000105020606020000000000014.9822.9136.2175.45152.21
0000.040.050.020.060.060.020000.561.15000000.010.040.040.180.15
0.060.360.250.910.891.111.451.370.810.670.440.931.592.380.851.213.891.710.81.210.561.161.682.37
4.57.846.575.954.928.066.633.291.890.493.82.663.642.537.644.568.838.299.248.566.227.0524.8621.99
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Immuron provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Immuron's financial health and stability.

Assets

Immuron's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Immuron must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Immuron after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Immuron's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (k)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
00000000000000000000-2-8-2-3
000000000000000000000000
000000000000000000000000
000001000000000011210003
000000000000000000000200
000000000000000000000000
000000000000000000000000
-1-1-10-1-1-2-2-2-2-2-1-2-2-2-3-5-7-3-1-3-4-3-2
0-10000000000000000000000
0-2101-222000000000000000-2
00101-222000000000000000-2
000000000000000000000000
00000000000000-1,00001,000-1,000000000
04000410104021902125212900
0400041010303270484212600
------------------2.00----2.00--
000000000000000000000000
-2-2-1-1-2-3-2-4-2-30-3-1-21-6-7-6-4-2-517-6-10
-1.13-3.61-2.01-0.86-1.35-1.9-2.87-3.01-2.09-2.08-2.26-1.99-2.46-2.06-2.67-3.02-5.16-7.04-3.51-1.8-3.15-4.09-3.16-2.6
000000000000000000000000

Immuron stock margins

The Immuron margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Immuron. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Immuron.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Immuron's sales revenue. A higher gross margin percentage indicates that the Immuron retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Immuron's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Immuron's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Immuron's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Immuron. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Immuron's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Immuron Margin History

Immuron Gross marginImmuron Profit marginImmuron EBIT marginImmuron Profit margin
202396.42 %-190.44 %-209.81 %
202268.41 %-407.4 %-373.01 %
202164.97 %-4,938.4 %-5,751.45 %
202072.65 %-121.97 %-116.23 %
201972.05 %-196.65 %-195.04 %
201888.66 %-76.58 %-81.52 %
201788.67 %-222.93 %-228.33 %
201692.46 %-131.47 %-140.12 %
201571.87 %-303.69 %-306.84 %
201468.27 %-187.5 %-244.23 %
201340 %-1,980 %-2,360 %
201221.74 %-552.17 %-500 %
201126.67 %-936.67 %-866.67 %
201044 %-434 %-380 %
200969.09 %-461.82 %-421.82 %
200875.23 %-294.5 %-262.39 %
200727.88 %-68.46 %-63.08 %
200646.36 %-67.98 %-74.01 %
200546.98 %-28.15 %-22.97 %
200444.99 %-34.73 %-27.04 %

Immuron Stock Sales Revenue, EBIT, Earnings per Share

The Immuron earnings per share therefore indicates how much revenue Immuron has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Immuron earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Immuron's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Immuron’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Immuron's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Immuron Revenue, EBIT and net profit per share

DateImmuron Sales per ShareImmuron EBIT per shareImmuron Earnings per Share
20230.01 undefined-0.02 undefined-0.02 undefined
20220 undefined-0.01 undefined-0.01 undefined
20210 undefined-0.03 undefined-0.04 undefined
20200.01 undefined-0.02 undefined-0.02 undefined
20190.02 undefined-0.03 undefined-0.03 undefined
20180.03 undefined-0.02 undefined-0.02 undefined
20170.03 undefined-0.06 undefined-0.06 undefined
20160.05 undefined-0.07 undefined-0.07 undefined
20150.01 undefined-0.05 undefined-0.05 undefined
20140.02 undefined-0.05 undefined-0.06 undefined
20130.01 undefined-0.21 undefined-0.25 undefined
20120.03 undefined-0.18 undefined-0.17 undefined
20110.02 undefined-0.22 undefined-0.2 undefined
20100.05 undefined-0.2 undefined-0.18 undefined
20090.1 undefined-0.46 undefined-0.42 undefined
20080.26 undefined-0.75 undefined-0.67 undefined
20071.31 undefined-0.9 undefined-0.83 undefined
20061.28 undefined-0.87 undefined-0.95 undefined
20051.56 undefined-0.44 undefined-0.36 undefined
20041.31 undefined-0.45 undefined-0.35 undefined

Immuron business model

Immuron Ltd was founded in 1994 and is headquartered in Melbourne, Australia. The company specializes in researching, developing, and marketing immunotherapy products. Immuron utilizes its patented technologies to develop and manufacture polyclonal antibodies and hyperimmune serums. The business model of Immuron focuses on selling immunotherapy products. The company concentrates on developing innovative products that address high medical needs and significantly improve the health of patients. Immuron operates in three divisions: gastrointestinal health, veterinary medicine, and infection control. Within these divisions, Immuron offers a variety of products tailored to specific needs. Gastrointestinal health is one of Immuron's key divisions. The company utilizes its expertise to develop products that protect and strengthen the human and animal intestine. Products in the gastrointestinal division include Travelan®, which is used for the prevention and treatment of traveler's diarrhea, and IMM-124E, which is used to treat inflammatory bowel diseases. It is also available in veterinary medicine. Veterinary medicine is another important pillar of Immuron's business. The company offers products tailored to the needs of animals. One notable product is the Immuron Canine® product line, used in the treatment of diarrhea in dogs. Additionally, the company has developed application-oriented research programs in infection control to aid veterinarians in improving the health of their animals. Immuron also has a division focused on infection control. The company develops and manufactures therapeutic products that target infections such as Helicobacter pylori and C. difficile. These products can contribute to reducing the use of antibiotics and antibiotic resistance. Over the years, Immuron has successfully brought several products to market. For example, Travelan® has been approved in Australia, Europe, and North America. Additionally, IMM-124E has been successfully tested in clinical studies in Canada and the United States and is currently undergoing the approval process in Europe. Overall, the company has a promising pipeline of products ready for market launch or phase II and III trials. These products have the potential to improve healthcare and enhance the quality of life for patients worldwide. Immuron has a strong foundation in immunotherapy research, which benefits the company in developing novel therapeutic options. Currently, Immuron is in a phase of growth, and it is likely that the company will achieve further success in the future. Immuron is one of the most popular companies on Eulerpool.com.

Immuron SWOT Analysis

Strengths

Immuron Ltd has several strengths that give it a competitive advantage in the market. Firstly, the company has a strong and experienced management team with a track record of success in the biotech industry. This provides a solid foundation for decision-making and strategy execution.

Additionally, Immuron Ltd has developed a unique platform technology that allows for the creation of novel and effective therapeutic products. This technology has the potential to revolutionize the treatment of certain diseases and provides the company with a distinct market edge.

The company also benefits from a diverse product portfolio, with multiple candidates in various stages of development. This diversity mitigates the risk associated with relying solely on one product and provides multiple revenue streams for the company.

Weaknesses

Despite its strengths, Immuron Ltd also faces certain weaknesses that need to be addressed. One key weakness is the company's limited financial resources. This constraint may hinder the company's ability to fully exploit its technology and commercialize its products.

Another weakness lies in the company's heavy dependence on its research and development pipeline. Delays or failures in the pipeline could significantly impact Immuron Ltd's revenue generation and overall growth prospects.

Opportunities

Immuron Ltd operates in an industry with immense growth potential. The rising prevalence of various diseases, coupled with increasing healthcare expenditure, presents significant opportunities for the company to expand its market reach and capture a larger share.

Furthermore, advancements in technology and the growing trend towards personalized medicine open doors for Immuron Ltd to develop targeted therapies tailored to individual patients, which can enhance treatment efficacy and drive demand for its products.

Threats

Immuron Ltd operates in a highly competitive landscape, with numerous biotech companies vying for market share. This intensifying competition poses a threat to the company's market position and profitability.

Additionally, regulatory uncertainty and stringent approval processes for new drugs and treatments can pose significant challenges for Immuron Ltd's product development and commercialization efforts.

Immuron Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Immuron historical P/E ratio, EBIT, and P/S ratio.

Immuron shares outstanding

The number of shares was Immuron in 2023 — This indicates how many shares 227.798 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Immuron earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Immuron's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Immuron’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Immuron's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Immuron Stock splits

In Immuron's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Immuron.

Immuron list of shareholders

%
Name
Stocks
Change
Date
2.63160 % Authentics Australia Pty. Ltd.6,000,00009/20/2023
2.14142 % Anastasiou (Stephen)4,882,38806/30/2023
1.68717 % Grandlodge Pty. Ltd.3,846,71209/20/2023
1.31580 % Hancock (Russell Kay)3,000,00009/20/2023
1.11916 % Karma Wealth Pty. Ltd.2,551,665651,6659/20/2023
1.01522 % Texas Woods Pty Ltd2,314,67409/20/2023
0.87720 % Gravcon Pty. Ltd.2,000,00009/20/2023
0.87720 % Insync Investments Pty Ltd2,000,00009/20/2023
0.66684 % Aston (Roger)1,520,37606/30/2023
0.65790 % Bird (William David Frank)1,500,00009/20/2023
1
2

Immuron Executives and Management Board

Dr. Jerry Kanellos60
Immuron Chief Operating Officer
Compensation 392,726
Dr. Roger Aston66
Immuron Non-Executive Director
Compensation 105,875
Mr. Daniel Pollock61
Immuron Non-Executive Independent Director
Compensation 94,875
Prof. Ravi Savarirayan55
Immuron Non-Executive Independent Director
Compensation 65,001
Mr. Stephen Anastasiou65
Immuron Non-Executive Independent Director
Compensation 65,000
1
2

Immuron Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Synlait Milk Stock
Synlait Milk
SupplierCustomer-0,170,570,460,180,52-
HSBC Holdings Stock
HSBC Holdings
SupplierCustomer-0,420,14-0,47-0,02-0,53-
Thermo Fisher Scientific Stock
Thermo Fisher Scientific
SupplierCustomer-0,550,090,38--0,59-
1

Most common questions regarding Immuron

What values and corporate philosophy does Immuron represent?

Immuron Ltd represents a commitment to developing novel immunotherapy solutions for infectious and inflammatory diseases. With a focus on gut health, the company aims to address unmet medical needs through its unique oral immunotherapeutic platform. Immuron actively engages in research and clinical trials to provide safe and effective treatments for conditions caused by microbial imbalances. By harnessing the power of the immune system, Immuron seeks to improve people's lives and contribute to advances in healthcare. The company's dedication to innovation and patient well-being underpins its corporate philosophy, driving its mission to revolutionize the field of immunotherapy.

In which countries and regions is Immuron primarily present?

Immuron Ltd is primarily present in Australia and the United States.

What significant milestones has the company Immuron achieved?

Immuron Ltd, a leading biopharmaceutical company, has achieved several significant milestones. Firstly, the company successfully completed a phase 2 clinical trial for its flagship product, IMM-124E, which demonstrated promising results in treating nonalcoholic steatohepatitis (NASH). Secondly, Immuron successfully obtained patents for its IMM-529 product, which aids in preventing travelers' diarrhea and helps military personnel. Moreover, the company expanded its market presence through strategic collaborations with top-tier organizations. Immuron also received regulatory approvals, such as from the FDA and TGA, further validating the effectiveness and safety of its products. These milestones highlight Immuron Ltd's commitment to innovation and its mission to improve global healthcare.

What is the history and background of the company Immuron?

Immuron Ltd, headquartered in Melbourne, Australia, is a biopharmaceutical company specializing in the development and commercialization of oral immunotherapeutics for the treatment and prevention of a range of gut-mediated diseases. Established in 1994, Immuron has a rich history of research and development in the field of immunotherapy. The company focuses on utilizing its proprietary technology platforms to create safe and effective treatments targeting gut-related disorders. With a strong commitment to innovation, Immuron has successfully brought multiple products to market and continues to advance its pipeline. Through strategic partnerships and collaborations, Immuron aims to expand its global presence and improve patient outcomes worldwide.

Who are the main competitors of Immuron in the market?

The main competitors of Immuron Ltd in the market include pharmaceutical companies such as Merck & Co., Inc., Pfizer Inc., and GlaxoSmithKline plc. These companies also focus on the development and commercialization of innovative medical treatments and therapies. Immuron Ltd faces competition in the biopharmaceutical sector, where companies strive to deliver groundbreaking products and solutions. It is essential for Immuron Ltd to leverage its unique technology, research capabilities, and collaborations to stay competitive and ensure its continued success in the market.

In which industries is Immuron primarily active?

Immuron Ltd is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Immuron?

The business model of Immuron Ltd revolves around developing and commercializing oral immunotherapy products for the treatment of various gut-mediated diseases. The company utilizes its proprietary technology platform to develop and manufacture these therapeutic products, which aim to restore and maintain a healthy balance of gut microflora. Through targeted research and clinical studies, Immuron aims to address unmet medical needs in areas such as diarrhea-predominant irritable bowel syndrome, nonalcoholic steatohepatitis, and liver diseases. By harnessing the potential of its therapeutic candidates, Immuron Ltd strives to improve the health and well-being of patients worldwide.

What is the P/E ratio of Immuron 2024?

The P/E ratio cannot be calculated for Immuron at the moment.

What is the P/S ratio of Immuron 2024?

The P/S cannot be calculated for Immuron currently.

What is the AlleAktien quality score of Immuron?

The AlleAktien quality score for Immuron is 2/10.

What is the revenue of Immuron 2024?

The revenue cannot currently be calculated for Immuron.

How high is the profit of Immuron 2024?

The profit cannot currently be calculated for Immuron.

What is the business model of Immuron

Immuron Ltd is an Australian-based biopharmaceutical company mainly engaged in the research and development of orally administered immunotherapies. The company focuses on combating life-threatening bacterial infections and immune system dysfunctions. Immuron's main business area is the development of IMM-124E, a medical product used for the treatment of non-alcoholic steatohepatitis (NASH) and other liver diseases. IMM-124E is a combination of milk antibodies and other active compounds aimed at reducing inflammation, liver cell damage, and fat accumulation in the liver. Immuron is also involved in the development of IMM-529, an orally administered product used for the prevention and treatment of traveler's diarrhea. It contains polyclonal antibodies produced against diarrhea-causing bacteria. The company has also started developing ImmunoN'hancer, another product that can be used for immunosuppression related to inflammatory bowel diseases and immunotherapy for various types of cancer. Immuron is also expanding into the field of animal health, offering a wide range of products including Oralzyme, a supplement to support dental and oral health in dogs and cats, and Travelan, used to prevent traveler's diarrhea in dogs and cats. In conclusion, Immuron is a leading player in immunotherapy and aims to improve patients' lives through its advanced products, innovative research, and strategic partnerships. The company is committed to sustainable development and strives to create products that are beneficial for both patient health and the environment.

What is the Immuron dividend?

Immuron pays a dividend of 0 AUD distributed over payouts per year.

How often does Immuron pay dividends?

The dividend cannot currently be calculated for Immuron or the company does not pay out a dividend.

What is the Immuron ISIN?

The ISIN of Immuron is AU000000IMC7.

What is the Immuron WKN?

The WKN of Immuron is A0RDPK.

What is the Immuron ticker?

The ticker of Immuron is IMC.AX.

How much dividend does Immuron pay?

Over the past 12 months, Immuron paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Immuron is expected to pay a dividend of 0 AUD.

What is the dividend yield of Immuron?

The current dividend yield of Immuron is .

When does Immuron pay dividends?

Immuron pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Immuron?

Immuron paid dividends every year for the past 0 years.

What is the dividend of Immuron?

For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Immuron located?

Immuron is assigned to the 'Health' sector.

Wann musste ich die Aktien von Immuron kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Immuron from 9/17/2024 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 9/17/2024.

When did Immuron pay the last dividend?

The last dividend was paid out on 9/17/2024.

What was the dividend of Immuron in the year 2023?

In the year 2023, Immuron distributed 0 AUD as dividends.

In which currency does Immuron pay out the dividend?

The dividends of Immuron are distributed in AUD.

All fundamentals about Immuron

Our stock analysis for Immuron Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Immuron Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.